Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The PReSUTINeB trial will investigate if Uro Vaxom can reduce the incidence of symptomatic UTIs in 48 participants in two centres in the UK (Stoke Mandeville Hospital, Buckinghamshire and Oxford Centre for Enablement). The trial has now recruited its first patient at the Oxford Centre for Enablement. The investigators will also look at the signs and symptoms a participant experiences during a symptomatic UTI.